Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.34 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450160 | 0.88 | GPR119 (0.49) | RETGPR119 | |
| SCHEMBL3667809 | 0.87 | RET (0.48) | RETKDRNPC1RAB9AALDH1A1 | |
| SCHEMBL1449741 | 0.86 | GPR119 (0.46) | RETPIP4K2CGPR119 | |
| SCHEMBL1450091 | 0.86 | RET (0.42) | RETMAPT | |
| SCHEMBL1449901 | 0.81 | RET (0.41) | RETPDGFRBKDREGFR | |
| SCHEMBL1450920 | 0.81 | ERBB2 (0.40) | RETKDREGFR | |
| SCHEMBL1449681 | 0.79 | GPR119 (0.45) | RETVNN1GPR119ALDH1A1 | |
| SCHEMBL1450162 | 0.78 | VNN1 (0.35) | RETVNN1MAPTGPR119 | |
| SCHEMBL1450209 | 0.78 | RET (0.38) | RETGPR119KDREGFR | |
| SCHEMBL11913130 | 0.78 | GPR119 (0.47) | RETGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513265-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130116237-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-8314095-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120202790-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| EP-2144902-B1 | [6,6]AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8076322-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110136783-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-09 | — | — | US | disclosed |
| US-7910583-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136783-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | RET 508/4885PDGFRB 660/4885VNN1 3969/4885 |
| US-20130116237-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | RET 508/4885PDGFRB 660/4885VNN1 3969/4885 |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | RET 508/4885PDGFRB 660/4885VNN1 3969/4885 |
| US-20120202790-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | RET 508/4885PDGFRB 660/4885VNN1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.